Alimera Sciences — FY2016 Earnings Presentation
13 slides from Alimera Sciences's earnings presentation, Mar 1, 2017
Slide 1: Fourth Quarter & Full Year 2016 Results Conference Call
Fourth Quarter & Full Year 2016 Results Conference Call Thursday, March 2, 2017 Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity for further growth in 2017 for ILUVIEN. Such forward-looking statements are based on current expec
Slide 3: 2016 Highlights
3 2016 Highlights Overall Revenue Growth 4Q16 $10.7M 4Q15 $5.8M +84% • Record revenues in the U.S. and Europe • Strengthened balance sheet with an equity raise and refinancing of our debt facility with Hercules • Advanced partnerships with distributors outside the United States to further the availa
Slide 4: Real World Data
4 Real World Data © 2017 Alimera Sciences, Inc., All Rights Reserved Clinical Data • We believe real world data from Europe provides evidence that ILUVIEN is working the same or better than in the FAME pivotal study, a result not typically seen in retina Podium & Presentations • 27 abstracts on ILUV
Slide 5: Advancing the Availability of ILUVIEN in 2017
5 Advancing the Availability of ILUVIEN in 2017 We expect Italy and the Middle East to have a positive impact on our international segment in the 2nd half of 2017 • In Italy – our distributor plans to launch in the 2nd quarter of 2017 • In the Middle East – our distributor expects to grow sales in 2
Slide 6: Financial Overview
Financial Overview Rick Eiswirth, President & CFO
Slide 7: Managing Our Spend
7 Managing Our Spend Because of our positive real world data, we are able to reduce the future spend of two large clinical trials: • Capped enrollment in our European registry study, awaiting final approval • Capped enrollment in Paladin study (U.S.), which will allow an earlier assessment of data ©
Slide 8: Fourth Quarter 2016 Revenues
8 Fourth Quarter 2016 Revenues 4Q15 $5.8M 4Q16 $10.7M +$4.9M 84% © 2017 Alimera Sciences, Inc., All Rights Reserved
Slide 9: U.S. Revenue Fourth Quarter and Full Year 2016
9 U.S. Revenue Fourth Quarter and Full Year 2016 4Q15 $3.9M 4Q16 $8.3M +$4.4M 113% Quarterly FY15 $15.2M FY16 $25.8M +$10.6M 70% Annual © 2017 Alimera Sciences, Inc., All Rights Reserved
Slide 10: International Revenue Fourth Quarter and Full Year 2016
10 International Revenue Fourth Quarter and Full Year 2016 4Q15 $1.9M 4Q16 $2.4M +$0.5M 26% Quarterly FY15 $7.3M FY16 $8.6M +$1.3M 18%% Annual © 2017 Alimera Sciences, Inc., All Rights Reserved
Slide 11: Select Balance Sheet Data
11 Select Balance Sheet Data ($000’s) As of December 31, 2016 As of December 31, 2015 Cash & Cash Equivalents $30,979 $31,075 Total Current Assets $47,402 $45,159 Total Assets $70,229 $70,484 Total Current Liabilities $9,123 $39,933 Total Stockholder’s Equity $25,586 $26,320 © 2017 Alimera Sciences,
Slide 12: Closing Remarks
Closing Remarks Dan Myers, CEO
Slide 13: Fourth Quarter & Full Year 2016 Results Conference Call
Fourth Quarter & Full Year 2016 Results Conference Call Thursday, March 2, 2017